Program License. Rigel and Pfizer each grants to the other a nonexclusive, worldwide, royalty-free license during the Research Period, including the right to grant sublicenses to Affiliates, to make and use Confidential Information, Program Technology and Product Patent Rights for the purpose of performing the Research Program; provided, however, that the other Party shall not acquire, by virtue of this Section or any other Section, any rights in the following:
Appears in 4 contracts
Samples: Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc), Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc), Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc)
